As 2025 draws to a close, it’s a great moment to reflect on what has been a landmark year for entX. Across all programs, we’ve built strong momentum - advancing our space-readiness initiatives, deepening international partnerships, securing key grant funding, and celebrating new patent awards that recognise our innovation and impact.

At our Advanced Radioisotope Production Facility in South Australia: early approvals are in hand, the construction contract awarded. Procurement underway for major equipment - including Hot Cells, advanced isotope purification technologies, and our EPA licensed laboratories - we’re translating plans into action. The team’s “boots on the ground” efforts are turning strategy into tangible progress at the Advanced Radioisotope Production Facility in South Australia, and momentum is building fast.

In our expanding space and defence portfolio, the successful manufacture and testing of prototype RHU (Radiation Heating Unit) systems at ANSTO have validated our engineering design and performance objectives as we prepare for a maiden launch in 2026. Construction of our dedicated GenX prototype manufacturing facility is also on track for completion in January 2026, positioning entX to play a leading role in powering the worlds emerging remote sensing, and deployment capabilities.

Supporting this strong operational performance has been the completion of $8.7 million in share placements to institutional, sophisticated, and professional investors, providing the capital depth to accelerate our next phase of development. We are also working under over $4.8 million in grant funding from the South Australian and Federal governments, pivotal in advancing our Advanced Radioisotope Production Facility and, in turn, strengthening Australia’s medical isotope manufacturing capability.

As IsoMedica moves toward full commercial readiness, our focus remains on scaling capabilities, strengthening governance, and driving disciplined investment to create enduring shareholder value. The foundations we’ve laid this year position entX strongly for sustainable growth, deeper industry collaboration, and leadership in Australia’s medical radioisotope and advanced nuclear technology landscape.

These achievements are a testament to the dedication of our people, the trust of our partners, and a shared mission to advance Australian nuclear science and next generation manufacturing. Looking ahead to 2026, we’re energised by the opportunities before us, continuing to deliver technologies that contribute to a safer, more sustainable, and resilient future.

Wishing you and your loved ones a joyful and safe Christmas, and heartfelt thanks for your support throughout the year.

Warm regards,

Bryn Jones

Managing Director